Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

340B Contract Pharmacies: Antivirals Are Top Drugs Dispensed

This article was originally published in The Pink Sheet Daily

Executive Summary

In the first study to analyze data for 340B-discounted drugs dispensed at contract retail pharmacies, researchers found antivirals were dispensed at more than 10 times the rate seen for all scripts at Walgreens, the largest 340B contract pharmacy. The largest source of 340B contract pharmacy prescriptions was tuberculosis clinics.

You may also be interested in...



Walgreens Participation In 340B Program Probed By Sen. Grassley

Grassley suggests concern that the big pharmacy chain’s participation in the program may lead to diversion, in which drugs purchased at discounted 340B pricing are dispensed to insured individuals, allowing the pharmacy to profit from the difference in payments.

GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds

New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.

Deal Watch: Sanofi, Boehringer Swap Side Businesses

Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS076687

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel